Ms. Daughtrey focuses her practice on intellectual property litigation and counseling. Ms. Daughtrey has experience representing companies in all stages of patent litigation from pre- suit investigation through trial and appeal. She also advises clients on patent-related due diligence.
Representative matters include:
- Genzyme Corporation, et al. v. Teva Pharmaceuticals USA, Inc., et al., No. 1:13-cv-01506 (D. Del.)
Representing Teva in an ongoing patent infringement litigation filed by Genzyme under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of Genzyme’s stem cell mobilizing agent, Mozobil® (plerixafor).
- Senju Pharmaceutical Co., Ltd., et al., v, Lupin Ltd., et al., No. 1:14-cv-6893 (D.N.J.)
Representing Lupin in an ongoing patent infringement litigation filed by Senju under the Hatch-Waxman Act in response to Lupin’s filing of an abbreviated new drug application seeking approval to market a generic version of Senju’s Prolensa® (bromfenac ophthalmic solution) medication.
- Glenmark Generics Ltd., et al. v. GlaxoSmithKline PLC, et al., No. 1:13-cv-00135 (D. Del.)
Representing Glenmark in a declaratory judgment action related to GlaxoSmithKline’s patents and Glenmark’s mupirocin cream.
- Prometheus Laboratories Inc. v. Roxane Laboratories, Inc., et al., No. 2:11-cv-01241 (D.N.J.)
Representing Roxane in a patent infringement litigation filed by Prometheus in response to Roxane’s filing of an abbreviated new drug application seeking approval to market a generic version of Prometheus’s IBS treatment drug, Lotronex® (alosetron hydrochloride). After a bench trial, the District Court found in favor of Roxane that Prometheus’s patent was invalid.
- Eli Lilly & Co. v. Teva Parenteral Medicines, Inc., et al., No. 10-cv-01376 (S.D. Ind.)
Representing Teva and Fresenius in a patent infringement litigation filed by Lilly under the Hatch-Waxman Act in response to Defendants’ respective filings of abbreviated new drug applications seeking approval to market generic versions of Lilly’s mesothelioma and non-small cell lung cancer treatment drug, Alimta® (pemetrexed disodium). The case is currently on appeal.
- ViiV Healthcare UK Ltd. et al. v. Teva Pharmaceuticals USA, Inc., No. 11-576-RGA (D. Del.)
Representing Teva in patent infringement litigation filed by ViiV under the Hatch-Waxman Act in response to Teva’s filing of an abbreviated new drug application seeking approval to market a generic version of ViiV’s EPZICOM® (abacavir sulfate and lamivudine) drug products.
